Wang Ai-Ping, Yang Fang, Tian Ying, Su Jian-Hui, Gu Qing, Chen Wei, Gong Shao-Xin, Ma Xiao-Feng, Qin Xu-Ping, Jiang Zhi-Sheng
Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang, China.
Department of Physiology, Institute of Neuroscience, Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment, Hengyang Medical College, University of South China, Hengyang, China.
Front Physiol. 2021 Apr 7;12:656139. doi: 10.3389/fphys.2021.656139. eCollection 2021.
Pulmonary hypertension (PH) is a critical and dangerous disease in cardiovascular system. Pulmonary vascular remodeling is an important pathophysiological mechanism for the development of pulmonary arterial hypertension. Pulmonary artery smooth muscle cell (PASMC) proliferation, hypertrophy, and enhancing secretory activity are the main causes of pulmonary vascular remodeling. Previous studies have proven that various active substances and inflammatory factors, such as interleukin 6 (IL-6), IL-8, chemotactic factor for monocyte 1, etc., are involved in pulmonary vascular remodeling in PH. However, the underlying mechanisms of these active substances to promote the PASMC proliferation remain to be elucidated. In our study, we demonstrated that PASMC senescence, as a physiopathologic mechanism, played an essential role in hypoxia-induced PASMC proliferation. In the progression of PH, senescence PASMCs could contribute to PASMC proliferation via increasing the expression of paracrine IL-6 (senescence-associated secretory phenotype). In addition, we found that activated mTOR/S6K1 pathway can promote PASMC senescence and elevate hypoxia-induced PASMC proliferation. Further study revealed that the activation of mTOR/S6K1 pathway was responsible for senescence PASMCs inducing PASMC proliferation via paracrine IL-6. Targeted inhibition of PASMC senescence could effectively suppress PASMC proliferation and relieve pulmonary vascular remodeling in PH, indicating a potential for the exploration of novel anti-PH strategies.
肺动脉高压(PH)是心血管系统中一种危急且危险的疾病。肺血管重塑是肺动脉高压发生发展的重要病理生理机制。肺动脉平滑肌细胞(PASMC)的增殖、肥大以及分泌活性增强是肺血管重塑的主要原因。以往研究证实,多种活性物质和炎性因子,如白细胞介素6(IL-6)、IL-8、单核细胞趋化因子1等,参与了PH中的肺血管重塑。然而,这些活性物质促进PASMC增殖的潜在机制仍有待阐明。在我们的研究中,我们证明PASMC衰老作为一种病理生理机制,在缺氧诱导的PASMC增殖中起重要作用。在PH的进展过程中,衰老的PASMC可通过增加旁分泌IL-6(衰老相关分泌表型)的表达来促进PASMC增殖。此外,我们发现激活的mTOR/S6K1通路可促进PASMC衰老并提高缺氧诱导的PASMC增殖。进一步研究表明,mTOR/S6K1通路的激活负责衰老的PASMC通过旁分泌IL-6诱导PASMC增殖。靶向抑制PASMC衰老可有效抑制PASMC增殖并缓解PH中的肺血管重塑,这表明探索新型抗PH策略具有潜力。